摘要
目的系统评价CYP2C19基因多态性对奥美拉唑药物代谢动力学的影响。方法计算机检索截止至2012年2月的Cochrane、PubMed、Embase、CNKI等数据库,收集有关CYP2C19基因多态性对奥美拉唑药动学影响的研究。用RevMan5.1软件对符合纳入标准的研究进行Meta分析。结果共纳入12篇回顾性研究。其中英文8篇,中文4篇。Meta分析结果表明,CYP2C19基因多态性显著影响ρmax、AUC、t1/2和CL/F。PM基因型组的ρmax、AUC和t1/2的值均大于HEM基因型组,且HEM基因型组均显著大于EM基因型组;基因型为EM人群的CL/F显著大于HEM基因型组,HEM人群的CL/F也显著大于HM基因型组。结论 CYP2C19基因多态性显著影响奥美拉唑的体内代谢,但其代谢还受多种其他因素影响,尚需高质量大样本量的前瞻性研究来证实。
OBJECTIVE To evaluate the influence of CYP2C19 genetic polymorphism on omeprazole pharmacokinetics. METH- ODS Cochrane library, PubMed, Embase and CNKI databases were searched for trials investigating the influence of CYP2C19 genet- ic polymorphism on omeprazole pharmacokinetics reported before February 2012. Meta-analysis was performed by RevMan 5.1 soft- ware. RESULTS Twelve retrospective studies, eight in English and four in Chinese, were included. Meta-analysis showed that CYP2C19 polymorphism significantly influenced the p AUC, tl/2 and CL/F. The p AUC, tl/2and CL/F in PM genotype group were higher than those in HEM group, and those in HEM group were significantly higher than in EM group. And the CL/F in EM group was significantly higher than that in HEM group followed by that in PM group. CONCLUSION CYP2C19 genetic polymorphism af- fects omeprazole exposure significantly, but there are still other influencing factors. Large prospective studies are needed.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2013年第5期374-379,共6页
Chinese Pharmaceutical Journal
